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Neuroblastoma (NB) is the third most common malignancy of childhood, and outcomes for children with advanced
disease remain poor; amplification of the MYCN gene portends a particularly poor prognosis. Mxi1 antagonizes
N-Myc by competing for binding to Max and E-boxes. Unlike N-Myc, Mxi1 mediates transcriptional repression and
suppresses cell proliferation. Mxi1 and Mxi1-0 (an alternatively transcribed Mxi1 isoform) share identical Max and
DNA binding domains but differ in amino-terminal sequences. Because of the conservation of these critical binding
domains, we hypothesized that Mxi1-0 antagonizes N-Myc activity similar to Mxi1. SHEP NB cells and SHEP cells
stably transfected with MYCN (SHEP/MYCN) were transiently transfected with vectors containing full-length Mxi1,
full-length Mxi1-0, or the common Mxi domain encoded by exons 2 to 6 (ex2-6). After incubation in low serum,
parental SHEP/MYCN cell numbers were reduced comparedwith SHEP cells. Activated caspase-3 staining and DNA
fragmentation ELISA confirmed that SHEP/MYCN cells undergo apoptosis in low serum, while SHEP/MYCN cells
transfected with Mxi1 or Mxi1-0 do not. However, SHEP/MYCN cells transfected with Mxi1 or Mxi1-0 and grown in
normal serum showed proliferation rates similar to SHEP cells. Mxi ex2-6 did not affect cell number in low or normal
serum, suggesting that amino terminal domains of Mxi1 and Mxi1-0 are critical for antagonism. In the absence of
N-Myc, Mxi1 and Mxi1-0 induce apoptosis independently through the caspase-8–dependent extrinsic pathway,
while N-Myc activates the caspase-9–dependent intrinsic pathway. Together, these data indicate that Mxi1 and
Mxi1-0 antagonize N-Myc but also independently impact NB cell survival.
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Neuroblastoma (NB) is the most common extracranial solid tumor in
children and the third most common pediatric cancer overall [1]. It
makes up 8% to 10% of all childhood cancers but accounts for a
disproportionate 15% of cancer-related deaths in children [1].
Current treatment for advanced stage NB includes high-dose
chemotherapy, radiation, and autologous hematopoietic stem cell
transplantation. However, despite intensive therapy, outcomes for
patients with advanced stage NB remain poor. Frequently, NB
initially responds to treatment but then returns, resistant to additional
therapeutic attempts. To improve outcomes in children with NB,
new therapies must be developed. Understanding the mechanisms by
which NB circumvents current therapies could aid in the
development of new therapeutic approaches.TheMYCN oncogene is amplified in one third of NB tumors, and
amplifiedMYCN is strongly associated with rapid disease progression
and poor prognosis [2–5]. AlthoughMYCN clearly serves as a marker
for advanced NB [6], the precise mechanisms by which MYCN and
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remain poorly understood. N-Myc belongs to the basic helix-loop-
helix leucine zipper (b-HLH-LZ) superfamily and to theMYC family
of proto-oncogenes that act as transcriptional activators of growth-
related target genes [7,8]. Myc proteins dimerize with the
ubiquitously expressed Max protein, bind to CACGTG (E-box)
sequences [9–11], and regulate cell proliferation and differentiation
[7,12–17], cell cycle control [18–20], and apoptosis [21–24]. In
addition, MYC genes play a pivotal role in the pathogenesis of
neoplasia [25]. Genetic alterations resulting in Myc overexpression
have been identified in a host of human malignancies, including
Burkitt lymphoma, glioblastoma, and medulloblastoma [26,27].
MYCN was originally cloned from NB cell lines by identifying
amplified DNA sequences with partial homology to the MYC proto-
oncogene [28,29]. As with other Myc family members, N-Myc binds
to and dimerizes with Max and binds to E-box sequences [30].
Amplification of MYCN has been shown to correlate with elevated
expression of N-Myc protein [31]. Ectopic expression of N-Myc in
cells leads to neoplastic transformation [32,33]. Additionally, directed
expression of N-Myc under control of the tyrosine hydroxylase
promoter leads to the development of NB tumors in transgenic mice
[34]. Conversely, MYCN antisense expression in NB cell lines results
in reduced cell proliferation, suggesting that antagonism of N-Myc
activity might reduce the aggressiveness ofMYCN-amplified NB [35].
The MAD gene family encodes proteins that have significant
homology to Myc and act as natural Myc antagonists [36–39]. The
MXI1 gene encodes the Mxi1 protein that binds Max and E-box
sequences like Myc but instead functions as a transcriptional repressor
[40–45]. Several studies have demonstrated the ability of Mxi1 to
counteract Myc-dependent transcription and transformation
[27,46,47]. The specific mechanisms by which Mxi1 produces its
repressive effects and regulates Myc activity remain to be determined.
While screening for upregulated genes in an NB cell line, our
laboratory discovered Mxi1-0, a novel Mxi1 isoform, translated from
an alternative transcript derived from a promoter upstream of a
previously unidentified exon (exon 0) [48]. Because Mxi1 and Mxi1-
0 share homology in the Max and E-box binding domains, we
hypothesized that like Mxi1, Mxi1-0 functions as a Myc antagonist.
Here, we examine the impact of N-Myc expression on NB cell
proliferation in both low and normal serum conditions. In addition,
we demonstrate that both Mxi1 andMxi1-0 are able to counteract the
effects of N-Myc in low and normal serum concentrations. Finally,
we show that Mxi1/Mxi1-0 activate distinct apoptotic pathways from
N-Myc, indicating that these transcription factors possess distinct
functions independent of their Myc inhibitory properties. Together,
these observations suggest that activation of Mxi1 and Mxi1-0 may
represent an attractive therapeutic target that both inhibits N-Myc
function and concurrently stimulates NB cell apoptosis.
Materials and Methods
Plasmid Construction
MXI1-0 and MXI1 cDNAs were amplified from a human heart
cDNA library (BD Biosciences-Clontech, Palo Alto, CA) using
BamH1 sequence containing forward primers (5′-CGGGATCCCA
TGGGCAAACGCGGGCGG-3′ and 5′-CGCGGATCCTCTAG
ACCATGGAGCGGGTGAAGATGATC-3′, respectively) and a
reverse primer (5′-CGCGGATCCTTAAGCGTAGTCTGGGA
CGTCGTATGGGTACAAGCTTGAAGTGAATGAAAGTTTGAC-3′) that includes coding sequence for an influenza hemag-
glutinin (HA) peptide epitope (YPYDVPDYA). This HA tag permits
detection of either Mxi1-0-HA or Mxi1-HA using anti-HA
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA). The
MXI1-0-HA and MXI1-HA cDNAs were subcloned into the
pcDNA3.1 eukaryotic expression vector (Invitrogen, Carlsbad,
CA). DNA sequencing was performed using the fluorescent dideoxy
terminator method of cycle sequencing on a PE/ABd 373a automated
DNA sequencer following ABd protocols at the University of
Michigan DNA Sequencing Core to confirm appropriate sequence
and orientation of each plasmid vector.
Cell Culture
SHEP and SHEP cells stably transfected with MYCN (SHEP/
MYCN) human NB cells (gift of Valerie Castle) were maintained in
RPMI-1640 supplemented with 10% FBS and 50 μg/ml penicillin/
streptomycin (Invitrogen-Gibco BRL, Rockville, MD) at 37°C in a
humidified atmosphere with 5% CO2. Cells were plated onto
100 mm × 20 mm tissue culture dishes (Corning, Corning, NY) and
passaged with 0.25% trypsin-EDTA (Invitrogen-Gibco). Cells were
plated at 1 × 105 cells per well in six-well plates (Corning)
for transfections.
Transfection
SHEP or SHEP/MYCN cells were transiently transfected with
pcDNA3.1 empty vector or pcDNA3.1 containing MXI1-0-HA,
MXI1-HA, or MXIex2-6-HA using TransIT-LT1 (Mirus, Madison,
WI). Briefly, 3 μl TransIT-LT1/1 μg plasmid DNA was added to
0.2 ml of Opti-MEM (Invitrogen-Gibco BRL) for 20 minutes. This
mixture was then added dropwise to cells in Opti-MEM media. After
24 hours, culture medium containing either 0.5% or 10% FBS was
added back to the cells.
Sodium Dodecyl Sulfate–Polyacrylamide Gel Electrophoresis
and Western Blot Analysis
Lysates from transfected SHEP and SHEP/MYCN cells were
collected in protein extraction buffer (160 mM NaCl, 65 mM Tris-
HCl, 2 mM EDTA, 1% sodium dodecyl sulfate, pH 8.0) containing
complete protease inhibitor cocktail (Roche, Indianapolis, IN). The
lysates were boiled after the addition of Laemmli sample buffer and
run on a 10% Tris-glycine gel (Bio-Rad, Hercules, CA). Proteins were
then transferred to Immobilon-P membranes by wet transfer
(Millipore, Bedford, MA). The membranes were blocked with 5%
milk and incubated with primary rabbit polyclonal antibodies to HA
(1:1000) or N-Myc (1:500; Santa Cruz Biotechnology). After
washing, the membranes were incubated with an HRP-linked goat
anti-rabbit secondary antibody (1:10,000; Jackson ImmunoResearch,
West Grove, PA). Band detection was achieved by the addition of ECL
Western Blotting Reagent and exposure to Hyperfilm ECL
(Amersham Biosciences, Piscataway, NJ).Immunocytochemistry
SHEP and SHEP/MYCN cells in 0.5% FBS were fixed with
methanol/acetone (1:1) 48 hours after transfection. Cells were then
blocked with 3% BSA and incubated with a primary antibody to
activated caspase-3 (1:250; Promega, Madison, WI) or HA (1:1,000;
Santa Cruz Biotechnology). After washing, the cells were incubated
with an Alexa Fluor 488 or 594-linked anti-rabbit secondary antibody
(1:100; Invitrogen-Molecular Probes, Eugene, OR). Cells were
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Carlsbad, CA) on a Nikon Eclipse E600 fluorescent microscope
(Melville, NY).
3-[4,5-Dimethylthiazol-2-yl]-Diphenyltetrazolium Bromide Assay
The reagent 3-[4,5-dimethylthiazol-2-yl]-diphenyltetrazolium
bromide (MTT; Sigma Chemical, St Louis, MO) was added at a
final concentration of 0.5 mg/ml (1:10 from a 5 mg/ml stock) to
SHEP and SHEP/MYCN cells in 0.5% or 10% FBS 96 hours after
transfection. After 1 hour at 37°C, the MTT/media was removed
from the cells and DMSO was added for 10 minutes. The DMSO
samples were transferred to a 96-well plate (Corning). Colorimetric
determination was performed at 490 nm using a SpectraMax Plus
microplate reader (Molecular Devices, Sunnyvale, CA).
Bromodeoxyuridine Cell Proliferation ELISA
Proliferation was assessed by bromodeoxyuridine (BrdU) incorpo-
ration using a kit as per the manufacturer’s instructions (Roche).
Briefly, BrdU was added to transfected SHEP and SHEP/MYCN
cells in 0.5% or 10% FBS and proliferation was allowed to occur for
96 hours. The cells were then fixed followed by incubation with a
peroxidase-conjugated antibody to BrdU. After washing, tetramethyl-
benzidine was added to the cells and color was allowed to develop for
20 minutes. Samples were transferred to 96-well plates (Corning).
Colorimetric determination was performed at 370 nm using a
SpectraMax Plus microplate reader (Molecular Devices).
DNA Fragmentation Apoptosis ELISA
Apoptosis was determined by the presence of cytoplasmic histone-
associated DNA fragments (mononucleosomes and oligonucleo-
somes) using a kit as per the manufacturer’s instructions (Roche).
Briefly, lysis buffer was added to SHEP and SHEP/MYCN 48 hours
after transfection and 24 hours after the addition of 10 μM caspase
inhibitor control (FMK) or inhibitors to caspase-3, caspase-8, or
caspase-9 (R&D Systems, Minneapolis, MN). The lysates were
centrifuged for 10 minutes to separate the cytoplasmic fraction from
intact nuclei and the supernatant was transferred to a 96-well
streptavidin-coated plate. An anti–histone-biotin and anti–DNA-
peroxidase mixture was added to the plate and incubated for 2 hours.
The plate was then washed, and 2,2′-azinobis[3-ethylbenzothiazoline-
6-sulfonic acid]-diammonium salt was added for 15 minutes.
Colorimetric determination was performed at 405 nm using a
microplate reader (Molecular Devices).
Statistical Analyses
The two-tailed Student’s t test was used to compare two groups.
Significance was considered to be P b .05. Data are reported as the
means ± SD unless otherwise stated. All assays were done in triplicate
and repeated at least three times.
Results
N-Myc Promotes NB Cell Proliferation in Normal Serum but
Inhibits Proliferation in Low Serum
We first examined whether expression of N-Myc in SHEP NB cells
alters cell proliferation. SHEP cells provide a good model for these
studies, as they do not express endogenous N-Myc. Although they do
express limited amounts of c-Myc, it is at levels much lower than
those seen in other malignant cell lines [49]. SHEP and SHEP/
MYCN were plated and incubated in either normal serum (10% FBS)or low serum (0.5% FBS) for 4 days to represent optimal growing
conditions or stress conditions, respectively. A cell viability assay was
used to detect differences in cell number. In normal serum, SHEP/
MYCN cells showed higher cell numbers than SHEP cells
(Figure 1A). In contrast, in low serum conditions, there were fewer
SHEP/MYCN cells than SHEP cells (Figure 1A). To establish that
the observed changes in cell number were due to changes in
proliferation rather than isolated increases in cell death rate, the
experiment was repeated with a BrdU proliferation ELISA
(Figure 1B). Similar trends were observed, with SHEP/MYCN cells
showing more BrdU incorporation when compared with SHEP cells
in normal serum with the converse observed in low serum. These
results indicate that N-Myc expression in SHEP cells leads to
increased cell proliferation in normal serum conditions but decreased
cell numbers under stress conditions.
Mxi1 and Mxi1-0 Antagonize the Effects of N-Myc on Cell
Proliferation and Apoptosis
Our laboratory previously described MXI1-0, an alternatively
transcribed isoform of MXI1. MXI1-0 retains exons 2 to 6 of MXI1
but splices out exon 1 in favor of an alternative exon (exon 0)
approximately 18 kb upstream of exon 1 [48]. However, the precise
function of Mxi1-0 in NB is unknown. Since Mxi1 is an N-Myc
antagonist, we used this system to determine the effects of Mxi1 and
Mxi1-0 on the N-Myc–induced changes previously observed in
SHEP and SHEP/MYCN cells. To further investigate the functional
role of Mxi1-0, we cloned MXI1 and MXI1-0 into an expression
vector. We also cloned exons 2 to 6, which are common between the
two transcription factors, without either exon 1 or exon 0 (Mxiex2-6)
to determine the importance of either first exon in the function of
these two proteins (Figure 2A). Each of these constructs, as well as an
empty pcDNA3.1 control vector, was separately transfected into
SHEP and SHEP/MYCN cells. To confirm expression and
comparable levels of these constructs after transfection, lysates were
collected after 48 hours and separated by polyacrylamide gel
electrophoresis. All constructs were expressed at relatively similar
levels, and SHEP/MYCN cells displayed N-Myc expression as
expected (Figure 2B). Expression of these constructs was also
confirmed by immunocytochemistry against Mxi1 and Mxi1-0
48 hours after transfection in SHEP and SHEP/MYCN cells
(Figure 3). Interestingly, Mxi1-0 appears to reside predominantly
in the cytoplasm, while Mxi1 and Mxiex2-6 localize primarily in
the nucleus.
After establishing consistent expression through transient transfec-
tion, SHEP and SHEP/MYCN cells were transfected with empty
vector, MXI1, MXI1-0, or MXIex2-6 (Mxi common region).
Twenty-four hours after transfection, cells were placed in low or
normal serum for 4 days. In low serum, SHEP cells transfected with
Mxi1 or Mxi1-0 showed fewer cells than empty vector or Mxiex2-6
transfected cells (Figure 4A). The same trend was observed for SHEP
cells in normal serum (Figure 4B). When SHEP/MYCN cells were
incubated in normal serum, the same pattern was observed
(Figure 4D). In contrast, in low serum conditions, expression of
Mxi1 or Mxi1-0 resulted in increased numbers of SHEP/MYCN cells
compared with empty vector or Mxiex2-6 (Figure 4C).
Since the MTT cell viability assay only measures cell number at a
specific time point and does not distinguish between cell proliferation
and cell death, experiments were performed using a BrdU
proliferation ELISA to investigate whether changes observed were
Figure 1. SHEP/MYCN cells exhibit higher cell numbers in normal serum and lower cell numbers in low serum than SHEP cells. SHEP and
SHEP/MYCN cells were plated and cultured in RPMI-1640 containing either low serum (0.5% FBS) or normal serum (10% FBS). After
96 hours, anMTT assay (A) or BrdU proliferation ELISA (B) was run, and the samples were read at 490 nm or 370 nm, respectively. *P b .05
when compared to SHEP cells in normal serum. #P b .05 when compared to SHEP cells in low serum.
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with SHEP cells in low and normal serum (Figure 5, A and B,
respectively). Similarly, SHEP/MYCN cells in normal serum
(Figure 5D) displayed less BrdU incorporation with Mxi1 or Mxi1-
0 transfected cells than with empty vector or Mxiex2-6 transfected
cells. Furthermore, SHEP/MYCN cells in low serum showed
increased BrdU incorporation when transfected with Mxi1 or
Mxi1-0 when compared with transfection with empty vector or
Mxiex2-6; this is also consistent with the results seen using the MTT
cell viability assay (Figure 5C). Together, these experiments suggest
that Mxi1 and Mxi1-0 expression leads to decreased SHEP cell
numbers regardless of serum concentration. In SHEP/MYCN cells,
however, Mxi1 and Mxi1-0 both abrogated the N-Myc–induced
increase in cell number in normal serum and prevented the decrease
in cell number in low serum, suggesting that both act as N-Myc
antagonists. Intriguingly, these observations raise the possibility that
Mxi1 and Mxi1-0 may also have effects distinct from solely
antagonizing N-Myc.Figure 2. Derivation of MXI1-0 and MXI1 transcripts. (A) MXI1
mRNA is transcribed from a promoter immediately upstream of
exon 1, whileMXI1-0 transcription initiates upstream of exon 0. The
three overexpressed proteins were Mxi1, Mxi1-0, and Mxiex2-6.
(B) Western blot of SHEP and SHEP/MYCN cells transfected with
either empty pcDNA3.1 vector or pcDNA3.1 containingMXI0-1-HA,
MXI1-HA, or MXIex2-6-HA. After 48 hours, lysates were collected,
run on sodium dodecyl sulfate–polyacrylamide gel electrophoresis,
and probed with antibodies to N-Myc or HA.N-Myc Expression Triggers Apoptosis in the Presence of Low Serum
We next explored the mechanism by which N-Myc expression is
associated with reduced SHEP/MYCN cell numbers in low serum.
On the basis of previous observations, we hypothesized that N-Myc
expression leads to increased rates of apoptosis in the presence of low
serum [50,51]. We again exposed SHEP and SHEP/MYCN cells to
either low or normal serum. After 48 hours, rate of apoptosis was
quantified using a DNA fragmentation ELISA (Figure 6). Not
surprisingly, the concentration of serum had no effect on the amount
of apoptosis in SHEP cells in the absence of N-Myc. In contrast,
incubating SHEP/MYCN cells in low serum led to a significant
increase in apoptosis. This suggests that N-Myc triggers apoptosis in
the presence of low serum.
To confirm that apoptosis was occurring, we examined SHEP and
SHEP/MYCN cells by immunohistochemical detection of activated
caspase-3 after incubation in low serum for 48 hours. Abundant
expression of activated caspase-3 in SHEP/MYCN cells transfected
with empty vector confirmed that expression of N-Myc leads to
apoptosis in low serum (Figure 7A). There was no substantial
apoptosis seen in SHEP cells, consistent with what we observed using
MTT and BrdU assays. We next examined whether N-Myc–
mediated apoptosis could be abrogated by expression of Mxi1 and
Mxi1-0. SHEP and SHEP/MYCN cells were transiently transfected
with Mxi1, Mxi1-0, or Mxiex2-6 vectors before growth in low serum
medium. As can be seen in Figure 7A, apoptosis triggered by N-Myc
was blocked by expression of Mxi1 and Mxi1-0, indicating
antagonism of N-Myc by Mxi1 and Mxi1-0. However, the Mxi
common region, Mxiex2-6, did not block apoptosis, suggesting that
exon 0 and exon 1 are critical for N-Myc antagonism. Interestingly,
SHEP cells transfected with Mxi1 or Mxi1-0 also showed activated
caspase-3 expression suggesting that they, too, were undergoing
apoptosis, while SHEP cells transfected with empty vector showed no
signs of apoptosis (Figure 7B). This observation further supports the
hypothesis that Mxi1 and Mxi1-0 may exert effects outside of their
N-Myc inhibitory capacity.Mxi1 and Mxi1-0 Activate Apoptosis through a Pathway
Distinct from N-Myc
To elucidate the mechanism of apoptosis in response to N-Myc
and Mxi1/Mxi1-0 expression, we repeated the MTT cell viability
assay with transfected SHEP and SHEP/MYCN but added caspase-3,
Figure 3. Mxi1-0, Mxi1, and Mxiex2-6 expression in SHEP and SHEP/MYCN cells. SHEP and SHEP/MYCN cells were transfected with
pcDNA3.1 containing MXI1-0-HA, MXI1-HA, or MXIex2-6-HA. After 48 hours, the cells were fixed with methanol/acetone and incubated
with a primary antibody to HA followed by a secondary antibody tagged with Alexa Fluor 488 (SHEP—green) or 594 (SHEP/MYCN—red).
Cells were visualized with a CoolSnap CCD camera on a Nikon Eclipse E600 fluorescent microscope.
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serum media. SHEP cells grown in low serum showed a pattern
similar to that seen in normal serum with caspase-3 and caspase-8, but
not caspase-9, preventing the difference in cell proliferation between
cells transfected with Mxi1 or Mxi1-0 and cells transfected with
empty vector or Mxiex2-6 (Figure 8A). Consistent with what was
seen in previous experiments, SHEP/MYCN cells in low serum
showed higher cell viability when transfected with Mxi1 or Mxi1-0
than empty vector or Mxiex2-6 transfected cells. The baselineFigure 4.Mxi1-0 and Mxi1 antagonize N-Myc–dependent proliferation
with either empty pcDNA3.1 vector or pcDNA3.1 containing MXI1-0
RPMI-1640 containing either low serum (0.5% FBS—A and C) or norm
performed. *P b .05 when compared to empty vector.decrease in cell viability mediated by N-Myc was blocked by
inhibitors to caspase-3 and caspase-9 but not caspase-8 (Figure 8B).
These results indicate that N-Myc mediates apoptosis in low serum
through the intrinsic apoptosis pathway by signaling through caspase-
3 and caspase-9. In contrast, the apoptotic pathway activated by Mxi1
and Mxi1-0 in the presence of N-Myc (SHEP) involves the extrinsic
pathway (caspase-8).
To assess the contributions of apoptosis compared with cell growth
inhibition under standard conditions, the above experiments were. SHEP (A and B) and SHEP/MYCN (C and D) cells were transfected
-HA, MXI1-HA, or MXIex2-6-HA. Cells were plated and cultured in
al serum (10% FBS—B and D). After 96 hours, an MTT assay was
Figure 5.Mxi1-0 and Mxi1 block N-Myc–dependent proliferation. SHEP (A and B) and SHEP/MYCN (C and D) cells were transfected with
either empty pcDNA3.1 vector or pcDNA3.1 containing MXI1-0-HA, MXI1-HA, or MXIex2-6-HA. Cells were plated and cultured in RPMI-
1640 containing either low serum (0.5% FBS—A and C) or normal serum (10% FBS—B and D). After 96 hours, a BrdU proliferation ELISA
was performed. *P b .05 when compared to empty vector.
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transfected with Mxi1 or Mxi1-0, MTT levels were less than those in
SHEP cells transfected with empty vector or Mxiex2-6 (Figure 8C).
The addition of an inhibitor to caspase-3 abrogated this difference,
with cells transfected with Mxi1 or Mxi1-0 showing the same amount
of MTT uptake as empty vector or Mxiex2-6 transfected cells
(Figure 8C). An inhibitor to caspase-8 also blocked this decrease, but
the caspase-9 inhibitor did not. In contrast, when SHEP/MYCN cells
were grown in normal serum, none of the caspase inhibitors blocked
the decrease in cell viability seen with Mxi1 or Mxi1-0 transfectionFigure 6. SHEP/MYCN cells undergo apoptosis in low serum.
SHEP and SHEP/MYCN cells were plated and cultured in RPMI-
1640 containing either low serum (0.5% FBS) or normal (10% FBS)
serum. After 48 hours, a DNA fragmentation apoptosis ELISA was
performed. *P b .05 when compared to SHEP at 0.5% FBS.when compared to empty vector or Mxiex2-6 transfection
(Figure 8D). These data confirm the observation that both Mxi1
and Mxi1-0 expression are able to block N-Myc–induced prolifer-
ation in SHEP/MYCN cells in normal serum rather than causing
apoptosis. However, these results also indicate that Mxi1 and Mxi1-0
induce apoptosis in the absence of N-Myc, suggesting that Mxi1 and
Mxi1-0 have functions independent of inhibiting N-Myc activity.
To confirm these differences, we used DNA fragmentation ELISA
to specifically examine apoptosis. SHEP cells grown in low serum
transfected with Mxi1 or Mxi1-0 showed increased apoptosis
compared with empty vector or Mxiex2-6 transfected cells
(Figure 9A). As expected, the caspase-3 and caspase-8 inhibitors
blocked Mxi1 and Mxi1-0–induced apoptosis, with levels similar to
those seen with empty vector and Mxiex2-6. In contrast, SHEP/
MYCN cells growing in low serum underwent apoptosis by activating
caspase-9 rather than caspase-8 as seen in SHEP cells. Additionally,
Mxi1 or Mxi1-0 transfection blocked the apoptosis seen in empty
vector or Mxiex2-6 transfected SHEP/MYCN cells grown in low
serum (Figure 9B). Furthermore, the caspase-9 inhibitor did not
block apoptosis in SHEP cells grown in low serum, and this same
pattern was observed for SHEP cells grown in normal serum
(Figure 9C). SHEP/MYCN cells grown in normal serum showed the
same level of apoptosis regardless of transfection with empty vector,
Mxi1, Mxi1-0, or Mxiex2-6, confirming that Mxi1 and Mxi1-0 were
not contributing to apoptosis in these cells (Figure 9D). Given the
activation of distinct apoptosis pathways, these data confirm the
hypothesis that Mxi1 and Mxi1-0 are able to affect proliferation
independently of their antagonism of N-Myc.
Discussion
NB is the most common extracranial solid tumor of childhood, and
despite intensive treatments, outcomes for children with advanced
Figure 7. SHEP and SHEP/MYCN cells have different patterns of apoptosis in low serum in the presence of Mxi1 andMxi1-0. SHEP/MYCN
(A) and SHEP (B) cells were transfected with either pcDNA3.1 empty vector or pcDNA3.1 containing MXI1-0-HA, MXI1-HA, or MXIex2-6-
HA. Cells were plated and cultured in RPMI-1640 containing low serum (0.5% FBS) for 48 hours. The cells were then fixed before
incubation with a primary antibody to activated caspase-3 for immunohistochemistry.
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only a fraction of patients with advanced stage NB; to achieve better
outcomes in this disease, new treatment modalities are needed.
Amplification of theMYCN oncogene is well known to be a predictorFigure 8. N-Myc affects apoptosis through caspase-3/caspase-9. SHE
either pcDNA3.1 empty vector or pcDNA3.1 containing MXI1-0-HA, M
1640 containing either low serum (0.5% FBS—A and B) or normal seru
caspase-8 (c8-i), or caspase-9 (c9-i) or a caspase inhibitor control (c-i-
compared to empty vector with caspase inhibitor control. %P b .05 whe
compared to Mxi1 with caspase inhibitor control.of poor outcome [5,6]. The Myc family of proteins plays a central role
in the regulation of cell growth and proliferation. Additionally, they
have been implicated in the etiology of several malignancies [25].
However, the mechanisms by which N-Myc leads to aggressive andP (A and C) and SHEP/MYCN (B and D) cells were transfected with
XI1-HA, or MXIex2-6-HA. Cells were plated and cultured in RPMI-
m (10% FBS—C and D) with or without inhibitors to caspase-3 (c3-i),
con). After 48 hours, an MTT assay was performed. *P b .05 when
n compared toMxi1-0 with caspase inhibitor control. #P b .05 when
Figure 9. N-Myc and Mxi1-0/Mxi1 induce apoptosis through different caspase pathways. SHEP (A and C) and SHEP/MYCN (B and D) cells
were transfected with either pcDNA3.1 empty vector or pcDNA3.1 containing MXI1-0-HA, MXI1-HA, or MXIex2-6-HA. Cells were plated
and cultured in RPMI-1640 containing either low serum (0.5% FBS—A and B) or normal serum (10% FBS—C and D) with or without
inhibitors to caspase-3 (c3-i), caspase-8 (c8-i), or caspase-9 (c9-i) or a caspase inhibitor control (c-i-con). After 48 hours, a DNA
fragmentation apoptosis ELISA was performed. *P b .05 when compared to empty vector with caspase inhibitor control. %P b .05 when
compared to Mxi1-0 with caspase inhibitor control. #P b .05 when compared to Mxi1 with caspase inhibitor control.
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the impact of excess N-Myc in the NB cell should lead to the
development of targeted new therapies.
The MAD family proteins, including Mxi1, are intrinsic inhibitors
of N-Myc function. Mxi1 plays an important role in controlling cell
growth and proliferation, and its loss of function has been implicatedFigure 10.Model of NB cell apoptosis induction under normal and
low serum conditions. N-Myc induces proliferation in normal
serum and apoptosis through caspase-9 (Casp9) in low serum.
Mxi1-0 and Mxi1 block these N-Myc–induced effects. In the
absence of amplified MYCN, Mxi1-0 and Mxi1 induce apoptosis
through caspase-8 (Casp8), regardless of serum concentration.in the formation of various malignancies, such as B-cell lymphoma
and glioblastoma [26,27]. Furthermore, expression of Mxi1 in
prostate cancer cells leads to decreased growth and proliferation [47].
In glioblastoma, Mxi1 overexpression also leads to growth arrest and
induction of apoptosis [27]. Furthermore, Mxi1 may be involved
in modulating tumor cell physiology. In NB, Mxi1 expression is
induced after exposure to hypoxic conditions and has been shown to
be involved in a hypoxia pathway involving hypoxia-inducible factor
1-alpha that can inhibit c-Myc–mediated apoptosis [52,53].
Furthermore, Mxi1 has been suggested to play a role in von
Hippel-Lindau–deficient tumorigenesis [54]. In the present study,
overexpression of Mxi1 in SHEP cells leads to apoptosis, which is not
surprising given its inhibitory effects on cell growth and proliferation.
Furthermore, Mxi1 antagonizes the effects of N-Myc when expressed
in SHEP/MYCN cells. In low serum, Mxi1 expression preserves
cell viability, while in normal serum, decreased cell proliferation is
observed. These results support an antagonistic function for Mxi1
in NB.
Mxi1-0 is an alternatively spliced variant of Mxi1. It contains an
alternative first exon (exon 0) while sharing exons 2 to 6 with Mxi1
[48]. In most systems, Mxi1-0 has not been shown to inhibit Myc
proteins but may actually act as an antagonist of Mxi1 by exerting a
dominant negative effect. For example, in glioblastoma, Mxi1-0 is
unable to inhibit c-Myc–dependent transcription [48]. A similar
dominant negative effect has also been demonstrated in esophageal
adenocarcinoma [55]. Furthermore, Mxi1-0 appears to localize in the
cytoplasm instead of the nucleus [48], suggesting that Mxi1-0 may act
by binding critical co-factors, such as Max and Sin3, and inhibit the
Translational Oncology Vol. 8, No. 1, 2015 Mxi1 and Mxi1-0 Antagonize N-Myc Function Erichsen et al. 73function of Mxi1. We observed the same pattern of localization in NB
cells (Figure 3). In addition, Mxi1-0 expression, along with Mxi1, is
increased under hypoxic conditions [53]. However, no changes were
observed in N-Myc–dependent gene transcription, indicating that
despite higher levels of Mxi1, it does not effectively inhibit N-Myc
transcriptional activity [53]. Intriguingly, we have recently demon-
strated that Mxi1-0 expression is upregulated in the presence of N-
Myc, with a concurrent decrease in Mxi1 expression [56]. This could
be a mechanism by which N-Myc decreases the activity of one of its
inhibitors (Mxi1). However, the results from the present study
suggest that like Mxi1, Mxi1-0 has N-Myc inhibitory properties as
well, at least when expressed at high levels. Given its ability to bind
Max and Sin3 like Mxi1, it is tempting to speculate that Mxi1-0 is
capable of modulating transcriptional activity in the proper context.
In the present study, we have investigated the role of Mxi1 and its
homolog,Mxi1-0, in the modulation of N-Myc function. Our findings
examine the inter-relationships among Mxi1, Mxi1-0, and N-Myc and
demonstrate a complex set of regulatory interactions among these
factors (Figure 10). In normal serum, N-Myc promotes cell growth and
proliferation, while in the presence of low serum, N-Myc triggers
apoptosis, a process requiring activation of caspase-9. A similar pro-
apoptotic role has been demonstrated for c-Myc after exposure of cells to
hypoxic conditions [57]. Under normal physiologic conditions, Myc
proteins induce cell growth and proliferation; however, under
conditions of stress (hypoxia, low growth factors), they can switch to
a pro-apoptotic role. Dysregulation of these functions may provide a
permissive environment for malignancies to thrive despite the non-ideal
physiologic conditions often found in tumors.
Intriguingly, our studies demonstrate that Mxi1 and Mxi1-0
induce apoptosis independently of N-Myc and that this activity is
dependent on their distinct amino terminal regions. The domain
common to Mxi1 and Mxi1-0 (exons 2-6) is unable to affect
apoptosis, although resulting alterations in protein structure due to
the elimination of amino terminal amino acids of the protein may
interfere with proper folding of the protein. Unlike the N-Myc–
mediated pathway, Mxi1 and Mxi1-0 activate caspase-8 to trigger
apoptosis. Caspase-8 is part of the extrinsic pathway of apoptosis,
which is typically activated by binding of death receptors of the tumor
necrosis factor receptor family (for review, see [58]). Binding of the
death receptor activates the Fas-associated death domain, leading to
the creation of the death-inducing signaling complex [58]. The death-
inducing signaling complex is able to recruit and activate caspase-8
and caspase-10, leading to activation of the apoptosis cascade.
Caspase-9, however, is activated through the internal pathway that is
triggered by mitochondrial cytochrome c release [58]. Our data
indicate that Mxi1 and Mxi1-0 are able to induce apoptosis by a
mechanism independent of their N-Myc inhibitory functions. The
mechanism by which Mxi1 and Mxi1-0 exert their pro-apoptotic
function is not clear but suggests a potential larger role for regulation
of cell growth and proliferation in NB outside of modulating the
transcriptional activity of N-Myc.
In summary, Mxi1 and Mxi1-0 function in NB to inhibit the
transcriptional activity of N-Myc. Additionally, they possess
independent anti-proliferative activity in the absence of N-Myc.
Given their role in preventing NB cell proliferation, Mxi1 and Mxi1-
0 or their downstream effectors may be potential targets to prevent
NB growth and to sensitize it to therapeutic agents. Further
understanding of the mechanisms of action of these two factors
may shed light on other potential targets for therapy.Acknowledgements
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